The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pharmacogenomics (PGx) Market Research Report 2025
Synopsis
The global Pharmacogenomics (PGx) market was valued at US$ 7757.9 million in 2023 and is anticipated to reach US$ 14590 million by 2030, witnessing a CAGR of 9.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics (PGx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics (PGx).
Report Scope
The Pharmacogenomics (PGx) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmacogenomics (PGx) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmacogenomics (PGx) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Affymetrix, Inc.
Assurex Health, Inc
Astrazeneca
GeneDX
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
Pathway Genomics
Pfizer, Inc
Qiagen, Inc.
Rocheg
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
Transgenomic, Inc.
Segment by Type
Polymerase Chain Reaction (PCR)
Microarray
Sequencing
Other
Segment by Application
Cardiovascular Diseases (CVD)
Central Nervous System (CNS)
Cancer/Oncology
Infectious Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmacogenomics (PGx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Pharmacogenomics (PGx) market was valued at US$ 7757.9 million in 2023 and is anticipated to reach US$ 14590 million by 2030, witnessing a CAGR of 9.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics (PGx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics (PGx).
Report Scope
The Pharmacogenomics (PGx) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmacogenomics (PGx) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmacogenomics (PGx) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Affymetrix, Inc.
Assurex Health, Inc
Astrazeneca
GeneDX
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
Pathway Genomics
Pfizer, Inc
Qiagen, Inc.
Rocheg
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
Transgenomic, Inc.
Segment by Type
Polymerase Chain Reaction (PCR)
Microarray
Sequencing
Other
Segment by Application
Cardiovascular Diseases (CVD)
Central Nervous System (CNS)
Cancer/Oncology
Infectious Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmacogenomics (PGx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics (PGx) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Microarray
1.2.4 Sequencing
1.2.5 Other
1.3 Market by Application
1.3.1 Global Pharmacogenomics (PGx) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cardiovascular Diseases (CVD)
1.3.3 Central Nervous System (CNS)
1.3.4 Cancer/Oncology
1.3.5 Infectious Diseases
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmacogenomics (PGx) Market Perspective (2019-2030)
2.2 Pharmacogenomics (PGx) Growth Trends by Region
2.2.1 Global Pharmacogenomics (PGx) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pharmacogenomics (PGx) Historic Market Size by Region (2019-2024)
2.2.3 Pharmacogenomics (PGx) Forecasted Market Size by Region (2025-2030)
2.3 Pharmacogenomics (PGx) Market Dynamics
2.3.1 Pharmacogenomics (PGx) Industry Trends
2.3.2 Pharmacogenomics (PGx) Market Drivers
2.3.3 Pharmacogenomics (PGx) Market Challenges
2.3.4 Pharmacogenomics (PGx) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics (PGx) Players by Revenue
3.1.1 Global Top Pharmacogenomics (PGx) Players by Revenue (2019-2024)
3.1.2 Global Pharmacogenomics (PGx) Revenue Market Share by Players (2019-2024)
3.2 Global Pharmacogenomics (PGx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmacogenomics (PGx) Revenue
3.4 Global Pharmacogenomics (PGx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics (PGx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics (PGx) Revenue in 2023
3.5 Pharmacogenomics (PGx) Key Players Head office and Area Served
3.6 Key Players Pharmacogenomics (PGx) Product Solution and Service
3.7 Date of Enter into Pharmacogenomics (PGx) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacogenomics (PGx) Breakdown Data by Type
4.1 Global Pharmacogenomics (PGx) Historic Market Size by Type (2019-2024)
4.2 Global Pharmacogenomics (PGx) Forecasted Market Size by Type (2025-2030)
5 Pharmacogenomics (PGx) Breakdown Data by Application
5.1 Global Pharmacogenomics (PGx) Historic Market Size by Application (2019-2024)
5.2 Global Pharmacogenomics (PGx) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Pharmacogenomics (PGx) Market Size (2019-2030)
6.2 North America Pharmacogenomics (PGx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pharmacogenomics (PGx) Market Size by Country (2019-2024)
6.4 North America Pharmacogenomics (PGx) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmacogenomics (PGx) Market Size (2019-2030)
7.2 Europe Pharmacogenomics (PGx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pharmacogenomics (PGx) Market Size by Country (2019-2024)
7.4 Europe Pharmacogenomics (PGx) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics (PGx) Market Size (2019-2030)
8.2 Asia-Pacific Pharmacogenomics (PGx) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pharmacogenomics (PGx) Market Size by Region (2019-2024)
8.4 Asia-Pacific Pharmacogenomics (PGx) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmacogenomics (PGx) Market Size (2019-2030)
9.2 Latin America Pharmacogenomics (PGx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pharmacogenomics (PGx) Market Size by Country (2019-2024)
9.4 Latin America Pharmacogenomics (PGx) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics (PGx) Market Size (2019-2030)
10.2 Middle East & Africa Pharmacogenomics (PGx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pharmacogenomics (PGx) Market Size by Country (2019-2024)
10.4 Middle East & Africa Pharmacogenomics (PGx) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Pharmacogenomics (PGx) Introduction
11.1.4 Abbott Laboratories Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 Affymetrix, Inc.
11.2.1 Affymetrix, Inc. Company Detail
11.2.2 Affymetrix, Inc. Business Overview
11.2.3 Affymetrix, Inc. Pharmacogenomics (PGx) Introduction
11.2.4 Affymetrix, Inc. Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.2.5 Affymetrix, Inc. Recent Development
11.3 Assurex Health, Inc
11.3.1 Assurex Health, Inc Company Detail
11.3.2 Assurex Health, Inc Business Overview
11.3.3 Assurex Health, Inc Pharmacogenomics (PGx) Introduction
11.3.4 Assurex Health, Inc Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.3.5 Assurex Health, Inc Recent Development
11.4 Astrazeneca
11.4.1 Astrazeneca Company Detail
11.4.2 Astrazeneca Business Overview
11.4.3 Astrazeneca Pharmacogenomics (PGx) Introduction
11.4.4 Astrazeneca Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.4.5 Astrazeneca Recent Development
11.5 GeneDX
11.5.1 GeneDX Company Detail
11.5.2 GeneDX Business Overview
11.5.3 GeneDX Pharmacogenomics (PGx) Introduction
11.5.4 GeneDX Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.5.5 GeneDX Recent Development
11.6 Illumina, Inc.
11.6.1 Illumina, Inc. Company Detail
11.6.2 Illumina, Inc. Business Overview
11.6.3 Illumina, Inc. Pharmacogenomics (PGx) Introduction
11.6.4 Illumina, Inc. Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.6.5 Illumina, Inc. Recent Development
11.7 Laboratory Corporation of America Holdings
11.7.1 Laboratory Corporation of America Holdings Company Detail
11.7.2 Laboratory Corporation of America Holdings Business Overview
11.7.3 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Introduction
11.7.4 Laboratory Corporation of America Holdings Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.7.5 Laboratory Corporation of America Holdings Recent Development
11.8 Myriad Genetics, Inc.
11.8.1 Myriad Genetics, Inc. Company Detail
11.8.2 Myriad Genetics, Inc. Business Overview
11.8.3 Myriad Genetics, Inc. Pharmacogenomics (PGx) Introduction
11.8.4 Myriad Genetics, Inc. Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.8.5 Myriad Genetics, Inc. Recent Development
11.9 Pathway Genomics
11.9.1 Pathway Genomics Company Detail
11.9.2 Pathway Genomics Business Overview
11.9.3 Pathway Genomics Pharmacogenomics (PGx) Introduction
11.9.4 Pathway Genomics Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.9.5 Pathway Genomics Recent Development
11.10 Pfizer, Inc
11.10.1 Pfizer, Inc Company Detail
11.10.2 Pfizer, Inc Business Overview
11.10.3 Pfizer, Inc Pharmacogenomics (PGx) Introduction
11.10.4 Pfizer, Inc Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.10.5 Pfizer, Inc Recent Development
11.11 Qiagen, Inc.
11.11.1 Qiagen, Inc. Company Detail
11.11.2 Qiagen, Inc. Business Overview
11.11.3 Qiagen, Inc. Pharmacogenomics (PGx) Introduction
11.11.4 Qiagen, Inc. Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.11.5 Qiagen, Inc. Recent Development
11.12 Rocheg
11.12.1 Rocheg Company Detail
11.12.2 Rocheg Business Overview
11.12.3 Rocheg Pharmacogenomics (PGx) Introduction
11.12.4 Rocheg Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.12.5 Rocheg Recent Development
11.13 Teva Pharmaceutical Industries Ltd.
11.13.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.13.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.13.3 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Introduction
11.13.4 Teva Pharmaceutical Industries Ltd. Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.13.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.14 Thermo Fisher Scientific
11.14.1 Thermo Fisher Scientific Company Detail
11.14.2 Thermo Fisher Scientific Business Overview
11.14.3 Thermo Fisher Scientific Pharmacogenomics (PGx) Introduction
11.14.4 Thermo Fisher Scientific Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.14.5 Thermo Fisher Scientific Recent Development
11.15 Transgenomic, Inc.
11.15.1 Transgenomic, Inc. Company Detail
11.15.2 Transgenomic, Inc. Business Overview
11.15.3 Transgenomic, Inc. Pharmacogenomics (PGx) Introduction
11.15.4 Transgenomic, Inc. Revenue in Pharmacogenomics (PGx) Business (2019-2024)
11.15.5 Transgenomic, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Industrial Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
